SCR-A014 / Simcere - LARVOL DELTA

SCR-A014, a novel bispecific ADC targeting B7H3 and DLL3 for SCLC therapy, exhibits potent anti-tumor efficacy (AACR 2026) - "These findings suggest that SCR-A014 is a potential first-in-class bispecific ADC and may offer a novel therapeutic strategy for SCLC cancers positive for B7H3 and DLL3."

ADC • Bispecific • Clinical • IO biomarker • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276 • CD86 • DLL3 • PD-L1